Tarlatamab-Dlle Application Scope

Imdelltra is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression on or after platinum-based chemotherapy.

Tarlatamab-dlle Characteristics

Specification: Supplied as a kit containing a vial of tarlatamab-dlle and an IV solution stabilizer
Ingredients: Tarlatamab-dlle is a bispecific delta-like ligand 3 (DLL3)-directed CD3 T-cell engager
Properties: Designed to redirect T-cells to target and kill DLL3-expressing tumor cells
Packaging Specification: Packaged as a kit with necessary components for intravenous administration
Storage: Store in a refrigerator at 2°C to 8°C (36°F to 46°F); do not freeze
Expiry Date: Dependent on the shortest expiration date of any component in the kit
Executive Standard: Approved under FDA Accelerated Approval Program
Approval Number: Biologics License Application (BLA) 761344
Date of Revision: May 16, 2024
Manufacturer: Amgen Inc.

Guidelines for the Use of Tarlatamab-dlle

Dosage and Administration:
Administered intravenously with a step-up dosing schedule to mitigate the risk of cytokine release syndrome (CRS). The recommended dosing is 3.2 mg/m² every 21 days until disease progression or unacceptable toxicity.

Adverse Reactions:

Common: Fatigue, pyrexia (fever), musculoskeletal pain
Serious: Cytokine release syndrome (CRS), neurologic toxicity including immune effector cell-associated neurotoxicity syndrome (ICANS), hepatotoxicity, hypersensitivity reactions during infusion, cytopenias (neutropenia, thrombocytopenia, anemia)

Contraindications:
Patients with known hypersensitivity to tarlatamab-dlle or any of its components.

Precautions:

Monitor for signs of CRS and neurologic toxicity; manage promptly.
Assess liver function tests before and during treatment.
Advise patients to avoid driving or operating machinery if experiencing dizziness, confusion, or other neurologic symptoms.

Interactions

Drug Interactions:
Has known interactions with 356 drugs, including 55 major and 301 moderate interactions. Notably, strong CYP3A inhibitors and inducers may affect tarlatamab-dlle metabolism.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.